Peru childhood vaccine schedule: 11 vaccines by age
For babies (first year): BCG (tuberculosis), Hepatitis B, DTaP / Tdap, Polio (IPV), Hib, Pneumococcal (PCV), Rotavirus, MMR, Hepatitis A, Influenza (flu). Click a vaccine for its Peru-specific page and its schedule in every other country.
| Vaccine | Status | Doses & recommended age |
|---|---|---|
| BCG (tuberculosis) · side effects & data | Universal | Dose 1 — At birth |
| Hepatitis B · side effects & data | Universal | Dose 1 — At birth Dose 2 — 2 months Dose 3 — 4 months Dose 4 — 6 months |
| DTaP / Tdap · side effects & data | Universal | Dose 1 — 2 months (Pentavalent then DTP) Dose 2 — 4 months (Pentavalent then DTP) Dose 3 — 6 months (Pentavalent then DTP) Booster — 18 months (Pentavalent then DTP) |
| Polio (IPV) · side effects & data | Universal | Dose 1 — 2 months (IPV then OPV) Dose 2 — 4 months (IPV then OPV) Dose 3 — 6 months (IPV then OPV) Booster — 18 months (IPV then OPV) Booster — 4 years (IPV then OPV) |
| Hib · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Dose 3 — 6 months |
| Pneumococcal (PCV) · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 4 months Booster — 12 months |
| Rotavirus · side effects & data | Universal | Dose 1 — 2 months (Rotavirus (oral)) Dose 2 — 4 months (Rotavirus (oral)) |
| MMR · side effects & data | Universal | Dose 1 — 12 months (SPR (MMR)) Dose 2 — 18 months (SPR (MMR)) |
| Hepatitis A · side effects & data | Universal | Dose 1 — 12 months |
| HPV · side effects & data | Universal | Dose 1 — 9-13 years Dose 2 — 6 months after dose 1 |
| Influenza (flu) · side effects & data | Universal | Annual — 6-24 months and risk groups, every season |
Peru vaccine schedule vs. the United States
Peru and the United States share 10 routine vaccines. Peru also routinely gives BCG (tuberculosis), which the U.S. does not. The U.S. routinely gives Varicella (chickenpox), Meningococcal, COVID-19, which Peru does not.
| Vaccine | Peru first dose | U.S. first dose | Doses |
|---|---|---|---|
| Hepatitis B | At birth | Birth | 4 vs 3 doses |
| DTaP / Tdap | 2 months | 2 months | 4 vs 5 doses |
| Polio (IPV) | 2 months | 2 months | 5 vs 4 doses |
| Hib | 2 months | 2 months | 3 vs 4 doses |
| Pneumococcal (PCV) | 2 months | 2 months | 3 vs 4 doses |
| Rotavirus | 2 months | 2 months | 2 vs 3 doses |
| MMR | 12 months | 12-15 months | 2 vs 2 doses |
| Hepatitis A | 12 months | 12-23 months | 1 vs 2 doses |
| HPV | 9-13 years | 11-12 years | 2 vs 2 doses |
| Influenza (flu) | 6-24 months and risk groups, every season | 6 months and older, every season | 1 vs 1 doses |
In the Peru schedule but not the routine U.S. schedule: BCG (tuberculosis).
In the routine U.S. schedule but not Peru's: Varicella (chickenpox), Meningococcal, COVID-19.
Why Peru's schedule looks the way it does
Schedules differ mostly because disease burden and health-system conditions differ. WHO/UNICEF estimates of how many children actually receive each vaccine, and the diseases' reported incidence, explain most of the choices below.
- Tuberculosis: 139 new cases per 100,000 people per year (2024) — about 43× the U.S. rate. BCG is given to every newborn nationwide. BCG mainly protects young children from severe TB (meningitis, miliary TB), so countries with high TB incidence give it at birth and low-incidence countries reserve it for risk groups.
- Measles: 0.1 reported cases per million people (2025). Two-dose coverage is 66%; sustained elimination needs roughly 95% coverage with both doses, which is why schedules add or move the second dose when coverage or outbreaks change.
- Hepatitis B birth dose: 83% coverage. A birth dose matters most where mothers commonly carry hepatitis B, because infection at birth becomes chronic in most infants; countries with low carriage and universal prenatal screening often start hepatitis B vaccination later or target only exposed newborns.
Coverage: share of children who received each vaccine (WHO/UNICEF estimates)
| Vaccine | Peru | United States |
|---|---|---|
| BCG (TB) | 87% (2025) | not reported |
| DTP dose 1 | 92% (2025) | 98% (2025) |
| DTP dose 3 | 84% (2025) | 94% (2025) |
| Measles dose 1 | 84% (2025) | 92% (2025) |
| Measles dose 2 | 66% (2025) | 95% (2025) |
| Polio (IPV series) | 84% (2025) | 93% (2025) |
| Hep B birth dose | 83% (2025) | 75% (2025) |
| Hep B dose 3 | 84% (2025) | 93% (2025) |
| Hib dose 3 | 84% (2025) | 92% (2025) |
| Pneumococcal (PCV) | 80% (2025) | 84% (2025) |
| Rotavirus (complete) | 87% (2025) | 77% (2025) |
| HPV dose 1, girls | 80% (2025) | 73% (2025) |
Source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and WHO reported incidence, via the WHO Immunization Data portal; TB incidence from the WHO Global Health Observatory (indicator MDG_0000000020). Retrieved 2026-10-09. "Not reported" usually means the vaccine is not in the universal schedule. Polio is the completed inactivated-polio series (IPVC).
Other Latin America countries
Argentina · Brazil · Chile · Colombia · Costa Rica · Ecuador · Honduras · Uruguay · all 31 countries